In this illustration, nanoparticles attach to or are taken up by the bacteria cells. Pan and his students are the first group to demonstrate that early detection of dental plaque in the clinic is possible using the regular intraoral X-ray machine which can seek out harmful bacteria populations.
When the good and bad bacteria in our mouth become imbalanced, the bad bacteria form a biofilm (aka plaque), which can cause cavities, and if left untreated over time, can lead to cardiovascular and other inflammatory diseases like diabetes and bacterial pneumonia.
A team of researchers from the University of Illinois has recently devised a practical nanotechnology-based method for detecting and treating the harmful bacteria that cause plaque and lead to tooth decay and other detrimental conditions.
Bioengineering Associate Professor Dipanjan Pan (seated) and doctoral student Fatemeh Ostadhossein have demonstrated a drug-free, nanotechnology-based method for detecting and destroying the bacteria that causes dental plaque.
Oral plaque is invisible to the eye so dentists currently visualize it with disclosing agents, which they administer to patients in the form of a dissolvable tablet or brush-on swab. While useful in helping patients see the extent of their plaque, these methods are unable to identify the difference between good and bad bacteria.
“Presently in the clinic, detection of dental plaque is highly subjective and only depends on the dentist’s visual evaluation,” said Bioengineering Associate Professor Dipanjan Pan, head of the research team. “We have demonstrated for the first time that early detection of dental plaque in the clinic is possible using the regular intraoral X-ray machine which can seek out harmful bacteria populations.”
In order to accomplish this, Fatemeh Ostadhossein, a Bioengineering graduate student in Pan’s group, developed a plaque detection probe that works in conjunction with common X-ray technology and which is capable of finding specific harmful bacteria known as Streptococcus mutans (S. mutans) in a complex biofilm network. Additionally, they also demonstrated that by tweaking the chemical composition of the probe, it can be used to target and destroy the S. mutans bacteria.
The probe is comprised of nanoparticles made of hafnium oxide (HfO2), a non-toxic metal that is currently under clinical trial for internal use in humans. In their study, the team demonstrated the efficacy of the probe to identify biochemical markers present at the surface of the bacterial biofilm and simultaneously destroy S. mutans. They conducted their study on Sprague Dawley rats.
In practice, Pan envisions a dentist applying the probe on the patient’s teeth and using the X-ray machine to accurately visualize the extent of the biofilm plaque. If the plaque is deemed severe, then the dentist would follow up with the administering of the therapeutic HfO2 nanoparticles in the form of a dental paste.
In their study, the team compared the therapeutic ability of their nanoparticles with Chlorhexidine, a chemical currently used by dentists to eradicate biofilm. “Our HfO2nanoparticles are far more efficient at killing the bacteria and reducing the biofilm burden both in cell cultures of bacteria and in [infected] rats,” said Ostadhossein, noting that their new technology is also much safer than conventional treatment.
The nanoparticles’ therapeutic effect is due, said Pan, to their unique surface chemistry, which provides a latch and kill mechanism. “This mechanism sets our work apart from previously pursued nanoparticle-based approaches where the medicinal effect comes from anti-biotics encapsulated in the particles,” said Pan, also a faculty member of the Carle Illinois College of Medicine and the Beckman Institute for Advanced Science and Technology. “This is good because our approach avoids anti-biotic resistance issues and it’s safe and highly scalable, making it well-suited for eventual clinical translation.”
Learn more: Novel nanoparticle-based approach detects and treats oral plaque without drugs
The Latest on: Oral plaque
via Google News
The Latest on: Oral plaque
- Philips Sonicare Diamondclean Sonic vs Oral B Genius 9000on March 1, 2021 at 4:02 am
To keep it simple - Oral-B toothbrushes make use of a rotary or oscillating mechanism, with its brush heads pulsating to loosen plaque and then oscillating to sweep it away, while Philips Sonicare ...
- Examining the impact of oral hygiene advice and/or scale and polish on periodontal disease: the IQuaD cluster factorial randomised controlled trialon February 25, 2021 at 4:00 pm
Objective To compare the clinical effectiveness and cost benefit of different frequencies of scale and polish (S&P) treatments in combination with different types of oral hygiene advice (OHA). Design ...
- Best electric toothbrushes 2021: teeth-whitening toothbrushes from Oral-B, Phillips, Foreo and Colgateon February 24, 2021 at 5:10 pm
Best electric toothbrushes 2021: teeth-whitening, plaque-fighting toothbrushes, from Oral-B, Phillips, Foreo and Colgate ...
- Wellness Wednesday: the link between oral health and heart healthon February 24, 2021 at 5:22 am
As we wrap up American Heart Month, there are several key things you should do now to keep your heart and your mouth healthy.
- Amgen submits sNDA to US FDA for Otezla to treat adults with mild-to-moderate plaque psoriasison February 24, 2021 at 2:30 am
Amgen submits sNDA to US FDA for Otezla to treat adults with mild-to-moderate plaque psoriasis: Thousand Oaks, California Wednesday, February 24, 2021, 16:00 Hrs [IST] Amgen annou ...
- Swish and pull your way to oral healthon February 23, 2021 at 4:57 pm
For thousands of years, the ancient Indian method of oil pulling has found its place in the dental care routines of several individuals, both young and old.
- Amgen Submits SNDA For Otezla For Adults With Mild-To-Moderate Plaque Psoriasison February 22, 2021 at 6:22 am
Amgen (AMGN) said that it has submitted a supplemental New Drug Application or sNDA to the U.S. Food and Drug Administration for Otezla or apremilast for the treatment of adults with mild-to-moderate ...
- Amgen Submits Supplemental New Drug Application for Otezla® (apremilast) for Adults with Mild-To-Moderate Plaque Psoriasison February 22, 2021 at 6:00 am
Amgen today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for Otezla ® for the treatment of adults with mild-to-moderate plaque psoriasis who ...
- Oral-B Genius 9000 reviewon February 19, 2021 at 6:36 am
A smart and reliable toothbrush with great performance, but still pretty pricey – even almost five years after launch ...
via Bing News